Prevention of recurrent erythema multiforme with lenalidomide: a case series-Reference-Cited by-同舟云学术

Prevention of recurrent erythema multiforme with lenalidomide: a case series

Published:2023-09-08 Issue:2 Volume:49 Page:166-168
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:

Author:

Ingen-Housz-Oro Saskia¹²³^ORCID,Joly Pascal²⁴,Kini-Matondo Willy⁵,Sbidian Emilie¹²³^ORCID

Affiliation:

1. Dermatology Department

2. Reference Center for Toxic Bullous Diseases and Severe Drug Reactions (TOXIBUL) , Créteil, France

3. University Paris Est Créteil Val de Marne EpiDermE , Créteil, France

4. Dermatology Department, Charles Nicolle University Hospital , Rouen , France

5. Pharmacy, AP-HP, Henri Mondor Hospital , Créteil, France

Abstract

Prevention of recurrences of erythema multiforme is a therapeutic challenge. Thalidomide is effective, but its use is limited by adverse effects, especially peripheral neuropathy. We report seven cases of recurrent severe erythema multiforme treated with lenalidomide. In six cases, the drug was effective without significant adverse effects.

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llad314/53710568/llad314.pdf

Reference10 articles.

1. Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment;Samim;Dent Clin North Am,2013

2. Autoantibodies against desmoplakin I and II define a subset of patients with erythema multiforme major;Foedinger;J Invest Dermatol,1996

3. A large epidemiological study of erythema multiforme in France, with emphasis on treatment choices;Kechichian;Br J Dermatol,2018

4. Interventions for erythema multiforme: a systematic review;de Risi-Pugliese;J Eur Acad Dermatol Venereol,2019

5. Evaluation of thalidomide treatment of patients with chronic erythema multiforme: a multicenter retrospective cohort study;Roux;JAMA Dermatol,2021